KCNQ2 and epilepsy: Retigabine (ezogabine), is a drug primarily acting as a positive allosteric modulator of KCNQ2-5 (Kv7.2–7.5) ion channels: it is the first neuronal potassium (K + ) channel opener licensed for the treatment of epilepsy [106].